Joshua David Lehsten, LISW | |
525 N Main St, Ada, OH 45810-1025 | |
(419) 422-8616 | |
Not Available |
Full Name | Joshua David Lehsten |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 525 N Main St, Ada, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1790266070 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | I.2103306 (Ohio) | Primary |
104100000X | Social Worker | S.1802782 (Ohio) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Joshua David Lehsten, LISW 316 Grandview Blvd, Ada, OH 45810-1662 Ph: (419) 296-6455 | Joshua David Lehsten, LISW 525 N Main St, Ada, OH 45810-1025 Ph: (419) 422-8616 |
News Archive
Even children of a healthy weight who have an imbalanced metabolism due to poor diet or exercise may be at increased risk of asthma, according to new research, which challenges the widespread assumption that obesity itself is a risk factor for asthma.
Promoting breastfeeding could lead to a substantial reduction in common infections and even deaths that are more common in Indigenous infants than non-Indigenous infants, a new study suggests.
In the light of the ongoing novel coronavirus epidemic in China, the US Food and Drug Administration has granted approval of a diagnostic test for use in emergency situations (emergency use authorization or EUA). The viral infection has spread to many different and distant parts of the world, involving over 25,000 people and causing nearly 600 deaths since it started in December 2019.
Personalized medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman's tumor and extend the time period between initial treatment and the cancer's return.
Researchers have conducted a study demonstrating the safety of administering a third (booster) dose of Pfizer-BioNTech's BNT162b2 vaccine.
› Verified 8 days ago